Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study
Extending docetaxel beyond six cycles in first-line mHSPC offers no survival advantage and increases toxicity. Six cycles remain an effective, pragmatic standard where triplet therapy is unavailable.
Authors
- Lena M. Unterrainer
- Isabel Brinkmann
- Can Aydogdu (ORCID: https://orcid.org/0009-0003-1486-183X)
- Melanie Götz
- Marina Hoffmann (ORCID: https://orcid.org/0000-0003-4776-0405)
- Frederik Kolligs
- Jozefina Casuscelli (ORCID: https://orcid.org/0000-0002-9899-1986)
- Benazir Enzinger
- Thilo Westhofen (ORCID: https://orcid.org/0000-0003-3812-5485)
- Florian Urban
- Leo F. Stadelmeier
- Volker Heinemann
- Severin Rodler
- Elena Berg
- Marie Semmler
- Alexander Tamalunas
- Christian G. Stief
Institutions
- LMU Klinikum (DE)
- University Hospital Schleswig-Holstein (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Urologia Internationalis
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1159/000550580
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00